Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,572 Shares

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,572 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $47.82, for a total value of $122,993.04. Following the completion of the transaction, the insider owned 158,165 shares in the company, valued at approximately $7,563,450.30. The trade was a 1.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, June 30th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.50, for a total value of $129,886.00.
• On Tuesday, June 17th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $59.75, for a total value of $153,677.00.
• On Monday, June 16th, Soleil Boughton sold 5,451 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.80, for a total value of $309,616.80.
• On Tuesday, May 27th, Soleil Boughton sold 3,233 shares of Hims & Hers Health stock. The stock was sold at an average price of $55.87, for a total value of $180,627.71.
• On Monday, April 28th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.19, for a total value of $97,694.84.

Hims & Hers Health Trading Up 2.6%

Shares of NYSE HIMS traded up $1.29 during mid-day trading on Wednesday, hitting $51.75. The company had a trading volume of 22,057,821 shares, compared to its average volume of 24,058,495. The company has a market capitalization of $11.58 billion, a price-to-earnings ratio of 75.00, a P/E/G ratio of 1.86 and a beta of 2.02. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The stock's 50-day moving average price is $53.89 and its 200-day moving average price is $41.45.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm's quarterly revenue was up 110.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.05 earnings per share. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after buying an additional 2,020,722 shares during the period. Farallon Capital Management LLC lifted its stake in Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Hims & Hers Health by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after purchasing an additional 40,447 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of recent analyst reports. Truist Financial set a $45.00 price target on Hims & Hers Health in a report on Tuesday, June 24th. Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Saturday. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Bank of America raised their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday, April 29th. Finally, Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $39.58.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.